Download PDF
Semin Respir Crit Care Med 2009; 30(1): 102-115
DOI: 10.1055/s-0028-1119814
© Thieme Medical Publishers

Tackling Empirical Antibiotic Therapy for Ventilator-Associated Pneumonia in Your ICU: Guidance for Implementing the Guidelines

Joseph L. Kuti1 , Eric Shore2 , 3 , Marc Palter4 , David P. Nicolau1 , 5
  • 1Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut
  • 2University of Connecticut, School of Medicine, Farmington, Connecticut
  • 3Division of Pulmonary/Critical Care, Hartford Hospital, Hartford, Connecticut
  • 4Division of Neurosurgery/Critical Care, Hartford Hospital, Hartford, Connecticut
  • 5Division of Infectious Diseases, Department of Medicine, Hartford Hospital, Hartford, Connecticut
Further Information

Publication History

Publication Date:
06 February 2009 (online)

    Permissions and Reprints

ABSTRACT

Guidelines published jointly by the American Thoracic Society and Infectious Diseases Society of America endorse the practice of appropriate empirical antibiotic therapy for ventilator-associated pneumonia (VAP) and even provide recommendations for specific antibiotics based on whether a patient has risk factors for multidrug-resistant infections. Unfortunately, the current guidelines provide little insight into how a specific institution can best develop a strategy for providing empirical antibiotic therapy. This review article focuses on important steps that should be taken in developing a hospital-specific pathway for the empirical antibiotic treatment of VAP. Consideration should be given to developing a multidisciplinary group to obtain intensive care unit (ICU)-specific antibiograms for the most common causative organisms, real-time minimum inhibitory concentration (MIC) data or MIC distributions from surveillance studies over a representable time frame, and implementing empirical dosage strategies aimed at achieving not only appropriate therapy but also optimal therapy based on pharmacodynamic targets. A proper deescalation strategy will also be vital to managing antibiotic choices and dosages, as well as providing useful recommendations for discontinuation of therapy. Finally, continued feedback of program results is critical to maintaining compliance as well as for reevaluating empirical antibiotic choices.

KEYWORDS

Pneumonia - ventilator - VAP - antibiotic - pharmacodynamics - pathway

REFERENCES

  • 1 American Thoracic Society and the Infectious Disease Society of America . Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.  Am J Respir Crit Care Med. 2005;  171 388-416
    CrossrefPubMedGoogle Scholar
  • 2 Craven D E, Kunches L M, Killinsky V, Lichtenberg D A, Make B J, McCabe W R. Risk factors for pneumonia and fatality in patients receiving continuous mechanical ventilation.  Am Rev Respir Dis. 1986;  133 792-796
    PubMedGoogle Scholar
  • 3 Chastre J, Fagon J Y. Ventilator-associated pneumonia.  Am J Respir Crit Care Med. 2002;  165 867-903
    CrossrefPubMedGoogle Scholar
  • 4 Fagon J Y, Chastre J, Hance A J, Montravers P, Novara A, Gibert C. Nosocomial pneumonia in ventilated patients: a cohort study evaluating attributable mortality and hospital stay.  Am J Med. 1993;  94 281-288
    CrossrefPubMedGoogle Scholar
  • 5 Rello J, Ollendorf D A, Oster G et al.. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database.  Chest. 2002;  122 2115-2121
    CrossrefPubMedGoogle Scholar
  • 6 Kollef M H, Silver P, Murphy D M, Trovillion E. The effect of late-onset ventilator-associated pneumonia in determining patient mortality.  Chest. 1995;  108 1655-1662
    CrossrefPubMedGoogle Scholar
  • 7 Valles J, Pobo A, Garcia-Esquirol O, Mariscal D, Real J, Fernandez R. Excess ICU mortality attributable to ventilator-associated pneumonia: the role of early vs late onset.  Intensive Care Med. 2007;  33 1363-1368
    CrossrefPubMedGoogle Scholar
  • 8 Pronovost P J, Miller M R, Dorman T, Berenholtz S M, Rubin H. Developing and implementing measures of quality of care in the intensive care unit.  Curr Opin Crit Care. 2001;  7 297-303
    CrossrefPubMedGoogle Scholar
  • 9 Berenholtz S M, Milanovich S, Faircloth A et al.. Improving care for the ventilated patient.  Jt Comm J Qual Saf. 2004;  30 195-204
    PubMedGoogle Scholar
  • 10 Isakow W, Kollef M H. Preventing ventilator-associated pneumonia: an evidence-based approach of modifiable risk factors.  Semin Respir Crit Care Med. 2006;  27 5-17
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Murray T, Goodyear-Bruch C. Ventilator-associated pneumonia improvement program.  AACN Adv Crit Care. 2007;  18 190-199
    PubMedGoogle Scholar
  • 12 Gastmeier P, Geffers C. Prevention of ventilator-associated pneumonia: analysis of studies published since 2004.  J Hosp Infect. 2007;  67 1-8
    CrossrefPubMedGoogle Scholar
  • 13 Health Care Performance Measurement Initiatives—2006. Available at: http://www.jointcommission.org/Physicians/md_pi.htm Accessed November 13, 2007
    Google Scholar
  • 14 Kollef M H, Sherman G, Ward S, Fraser V J. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients.  Chest. 1999;  115 462-474
    CrossrefPubMedGoogle Scholar
  • 15 Iregui M, Ward S, Sherman G, Fraser V J, Kollef M H. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia.  Chest. 2002;  122 262-268
    CrossrefPubMedGoogle Scholar
  • 16 Luna C M, Aruj P, Niederman M S et al.. Appropriateness and delay to initiate therapy in ventilator-associated pneumonia.  Eur Respir J. 2006;  27 158-164
    CrossrefPubMedGoogle Scholar
  • 17 Rello J, Diaz E. Pneumonia in the intensive care unit.  Crit Care Med. 2003;  31 2544-2551
    CrossrefPubMedGoogle Scholar
  • 18 Rello J, Sa-Borges M, Correa H, Leal S R, Baraibar J. Variations in etiology of ventilator-associated pneumonia across four treatment sites: implications for antimicrobial prescribing practices.  Am J Respir Crit Care Med. 1999;  160 608-613
    CrossrefPubMedGoogle Scholar
  • 19 Styers D, Sheehan D J, Hogan P, Sahm D F. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States.  Ann Clin Microbiol Antimicrob. 2006;  5 2
    CrossrefPubMedGoogle Scholar
  • 20 Nicasio A M, Kuti J L, Nicolau D P. The current state of multidrug-resistant gram-negative bacilli in North America: insights from the Society of Infectious Diseases Pharmacists.  Pharmacotherapy. 2008;  28 235-249
    CrossrefPubMedGoogle Scholar
  • 21 Beardsley J R, Williamson J C, Johnson J W, Ohl C A, Karchmer T B, Bowton D L. Using local microbiological data to develop institution-specific guidelines for the treatment of hospital-acquired pneumonia.  Chest. 2006;  130 787-793
    CrossrefPubMedGoogle Scholar
  • 22 Green D L. Selection of an empiric antibiotic regimen for hospital-acquired pneumonia using a unit and culture-type specific antibiogram.  J Intensive Care Med. 2005;  20 296-301
    CrossrefPubMedGoogle Scholar
  • 23 Binkley S, Fishman N O, Larosa L A et al.. Comparison of unit-specific and hospital-wide antibiograms: potential implications for selection of empirical antimicrobial therapy.  Infect Control Hosp Epidemiol. 2006;  27 682-687
    CrossrefPubMedGoogle Scholar
  • 24 Eagye K J, Shore E, Dobkin E, Palter M, Nicolau D P, Kuti J L. Differing epidemiology and resistance patterns of respiratory isolates from three intensive care units within the same institution [abstract K-0259]. In: Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy Washington, DC; American Society of Microbiology 2006: 304
    Google Scholar
  • 25 Clinical and Laboratory Standards Institute (CLSI) .Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data: Approved Guideline. 2nd ed. CLSI document M39–A2 Wayne, PA; Clinical and Laboratory Standards Institute 2005
    Google Scholar
  • 26 Mohr J F, Wanger A, Rex J H. Pharmacokinetic/pharmacodynamic modeling can help guide targeted antimicrobial therapy for nosocomial gram-negative infections in critically ill patients.  Diagn Microbiol Infect Dis. 2004;  48 125-130
    CrossrefPubMedGoogle Scholar
  • 27 Bouza E, Torres M V, Radice C et al.. Direct E-test (AB BIODISK) of respiratory samples improves antimicrobial use in ventilator-associated pneumonia.  Clin Infect Dis. 2007;  44 382-387
    CrossrefPubMedGoogle Scholar
  • 28 Gillespie E L, Kuti J L, Nicolau D P. When “S” doesn't mean success: the importance of choice of antibiotic and dose on clinical and economic outcomes of severe infections.  Conn Med. 2005;  69 203-210
    PubMedGoogle Scholar
  • 29 Drusano G L. Antimicrobial pharmacodynamics: critical interactions of “bug and drug.”  Nat Rev Microbiol. 2004;  2 289-300
    CrossrefPubMedGoogle Scholar
  • 30 Craig W A. Pharmacokinetics/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.  Clin Infect Dis. 1998;  26 1-10
    CrossrefPubMedGoogle Scholar
  • 31 Turnidge J D. The pharmacodynamics of β-lactams.  Clin Infect Dis. 1998;  27 10-22
    Google Scholar
  • 32 Li J, Turnidge J, Milne R, Nation R L, Coulthard K. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis.  Antimicrob Agents Chemother. 2001;  45 781-785
    CrossrefPubMedGoogle Scholar
  • 33 Moore R D, Smith C R, Lietman P S. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia.  J Infect Dis. 1984;  149 443-448
    CrossrefPubMedGoogle Scholar
  • 34 Moore R D, Lietman P S, Smith C R. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration.  J Infect Dis. 1987;  155 93-99
    CrossrefPubMedGoogle Scholar
  • 35 Preston S L, Drusano G L, Berman A L et al.. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials.  JAMA. 1998;  279 125-129
    CrossrefPubMedGoogle Scholar
  • 36 Freeman C D, Nicolau D P, Belliveau P P, Nightingale C H. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice.  J Antimicrob Chemother. 1997;  39 677-686
    CrossrefPubMedGoogle Scholar
  • 37 Nicolau D P, Freeman C D, Belliveau P P, Nightingale C H, Ross J W, Quintiliani R. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients.  Antimicrob Agents Chemother. 1995;  39 650-655
    PubMedGoogle Scholar
  • 38 Kashuba A D, Nafziger A N, Drusano G L, Bertino J S. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria.  Antimicrob Agents Chemother. 1999;  43 623-629
    PubMedGoogle Scholar
  • 39 Kuti J L, Nicasio A M, Shore E, Palter M, Pepe J, Nicolau D P. Outcomes of an empiric antibiogram algorithm (EAA) for ventilator associated pneumonia (VAP) that considers local MIC distributions and pharmacodynamics (PD) [abstract 1093]. 45th Annual Meeting of the Infectious Diseases Society of America San Diego, CA; October 4–7, 2007
    Google Scholar
  • 40 Lacy M K, Lu W, Xu X et al.. Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection.  Antimicrob Agents Chemother. 1999;  43 672-677
    PubMedGoogle Scholar
  • 41 Wright D H, Brown G H, Peterson M L, Rotschafer J C. Application of fluoroquinolone pharmacodynamics.  J Antimicrob Chemother. 2000;  46 669-683
    CrossrefPubMedGoogle Scholar
  • 42 Forrest A, Nix D E, Ballow C H, Goss T F, Birmingham M C, Schentag J J. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients.  Antimicrob Agents Chemother. 1993;  37 1073-1081
    CrossrefPubMedGoogle Scholar
  • 43 Ambrose P G, Grasela D M, Grasela T H, Passarell J, Mayer H B, Pierce P F. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections.  Antimicrob Agents Chemother. 2001;  45 2793-2797
    CrossrefPubMedGoogle Scholar
  • 44 Drusano G L, Preston S L, Fowler C, Corrado M, Weisinger B, Kahn J. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia.  J Infect Dis. 2004;  189 1590-1597
    CrossrefPubMedGoogle Scholar
  • 45 Deryke C A, Kuti J L, Nicolau D P. Re-evaluation of current susceptibility breakpoints for gram-negative rods based on pharmacodynamic assessment.  Diagn Microbiol Infect Dis. 2007;  58 337-344
    CrossrefPubMedGoogle Scholar
  • 46 Deryke C A, Kuti J L, Nicolau D P. Pharmacodynamic target attainment of six β-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004.  Pharmacotherapy. 2007;  27 333-342
    CrossrefPubMedGoogle Scholar
  • 47 Sun H K, Kuti J L, Nicolau D P. Pharmacodynamics of antimicrobials for the empiric treatment of nosocomial pneumonia: a report from the OPTAMA Program.  Crit Care Med. 2005;  33 2222-2227
    CrossrefPubMedGoogle Scholar
  • 48 Mattoes H M, Kuti J L, Drusano G L, Nicolau D P. Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem.  Clin Ther. 2004;  26 1187-1198
    CrossrefPubMedGoogle Scholar
  • 49 Kim A, Sutherland C A, Kuti J L, Nicolau D P. Optimal dosing of piperacillin/tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?.  Pharmacotherapy. 2007;  27 1490-1497
    CrossrefPubMedGoogle Scholar
  • 50 Zosyn (piperacillin/tazobactam for injection) package insert. Collegeville, PA; Wyeth Pharmaceuticals 2005
    Google Scholar
  • 51 Ludwig E, Konkoly-Thege M, Kuti J L, Nicolau D P. Optimizing antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian Hospitals.  Int J Antimicrob Agents. 2006;  28 433-438
    CrossrefPubMedGoogle Scholar
  • 52 Kuti J L, Moss K M, Nicolau D P, Knauft R F. Empiric treatment of multidrug-resistant Burkholderia cepacia lung exacerbation in a patient with cystic fibrosis: Application of pharmacodynamic concepts to meropenem therapy.  Pharmacotherapy. 2004;  24 1641-1645
    CrossrefPubMedGoogle Scholar
  • 53 Lodise Jr T P, Lomaestro B M, Drusano G L. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.  Clin Infect Dis. 2007;  44 357-363
    CrossrefPubMedGoogle Scholar
  • 54 Rybak M J. The pharmacokinetic and pharmacodynamic properties of vancomycin.  Clin Infect Dis. 2006;  42 S35-S39
    CrossrefPubMedGoogle Scholar
  • 55 Moise P A, Forrest A, Bhavnani S M, Birmingham M C, Schentag J J. Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. .  Am J Health Syst Pharm. 2000;  57(Suppl 2) S4-9
    PubMedGoogle Scholar
  • 56 Moise-Broder P A, Forrest A, Birmingham M C, Schentag J J. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.  Clin Pharmacokinet. 2004;  43 925-942
    CrossrefPubMedGoogle Scholar
  • 57 Sakoulas G, Moise-Broder P A, Schentag J, Forrest A, Moellering R C, Eliopoulus G M. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia.  J Clin Microbiol. 2004;  42 2398-2402
    CrossrefPubMedGoogle Scholar
  • 58 Soriano A, Marco F, Martinez J A et al.. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia.  Clin Infect Dis. 2008;  46 193-200
    CrossrefPubMedGoogle Scholar
  • 59 Kuti J L, Kiffer C RV, Mendes C MF, Nicolau D P. Pharmacodynamic comparison of linezolid, teicoplanin, and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil.  Clin Microbiol Infect. 2008;  14 116-123
    PubMedGoogle Scholar
  • 60 Hidayat L K, Hsu D I, Quist R, Shriner K A, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.  Arch Intern Med. 2006;  166 2138-2144
    CrossrefPubMedGoogle Scholar
  • 61 Rello J, Vidaur L, Sandiumenge A et al.. De-escalation therapy in ventilator-associated pneumonia.  Crit Care Med. 2004;  32 2183-2190
    PubMedGoogle Scholar
  • 62 Micek S T, Ward S, Fraser V J, Kollef M H. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia.  Chest. 2004;  125 1791-1799
    CrossrefPubMedGoogle Scholar
  • 63 Ibrahim E H, Ward S, Sherman G, Schaiff R, Fraser V J, Kollef M H. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia.  Crit Care Med. 2001;  29 1109-1115
    CrossrefPubMedGoogle Scholar
  • 64 Kollef M H, Kollef K E. Antibiotic utilization and outcomes for patients with clinically suspected ventilator-associated pneumonia and negative quantitative BAL culture results.  Chest. 2005;  128 2706-2713
    CrossrefPubMedGoogle Scholar
  • 65 Chastre J, Wolff M, Fagon J Y et al.. Comparison of 8 vs. 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial.  JAMA. 2003;  290 2588-2598
    CrossrefPubMedGoogle Scholar
  • 66 Soo Hoo G W, Wen Y E, Nguyen T V, Goetz M B. Impact of clinical guidelines in the management of severe hospital-acquired pneumonia.  Chest. 2005;  128 2778-2787
    CrossrefPubMedGoogle Scholar
  • 67 Evans R S, Pestotnik S L, Classen D C et al.. A computer-assisted management program for antibiotics and other antiinfective agents.  N Engl J Med. 1998;  338 232-238
    Google Scholar
  • 68 Dellit T H, Owens R C, McGowan J E et al.. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship.  Clin Infect Dis. 2007;  44 159-177
    CrossrefPubMedGoogle Scholar

Joseph L KutiPharm.D. 

Center for Anti-Infective Research and Development, Hartford Hospital

80 Seymour St., Hartford, CT 06102

Email: jkuti@harthosp.org

      >